ArticleThe Korean journal of internal medicine2012
Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.
Article in The Korean journal of internal medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review.Journal of diabetes research · 2020Pooled it
- Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.Journal of the American Society of Nephrology : JASN · 2015Trial
- Astragaloside IV attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation.Frontiers in pharmacology · 2024Article
- Chronic sildenafil citrate use decreases retinal vascular endothelial growth factor expression in diabetic rats: a pilot study.International journal of retina and vitreous · 2023Article
- The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease.Molecules (Basel, Switzerland) · 2022Review
- Ferroptosis Enhanced Diabetic Renal Tubular InjuryFrontiers in endocrinology · 2021Article
- Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?Kidney360 · 2020Review
- Evolving spectrum of diabetic nephropathy.World journal of diabetes · 2019Review
- The Level of Serum Albumin Is Associated with Renal Prognosis in Patients with Diabetic Nephropathy.Journal of diabetes research · 2019Article
- Fresh Pomegranate Juice Decreases Fasting Serum Erythropoietin in Patients with Type 2 Diabetes.International journal of food science · 2019Article
- The effects of ozone therapy on caspase pathways, TNF-α, and HIF-1α in diabetic nephropathy.International urology and nephrology · 2016Article
- Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?Current hypertension reports · 2016Review
- Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Article
- Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase.Journal of inflammation (London, England) · 2015Article
- Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model.International journal of endocrinology · 2014Article
- The renoprotective effects of pentoxifylline: beyond its role in diabetic nephropathy.The Korean journal of internal medicine · 2013Article
- Effect of phosphodiesterase inhibitor on diabetic nephropathy.The Korean journal of internal medicine · 2012Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byIn reply.2013
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsRenal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a nonselective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney.
methodsPTX (40 mg/kg, p.o.) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue hypoxia, we examined hypoxic inducible factor-1α (HIF-1α), heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1α in renal tubule cells.
resultsPTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1α, VEGF, and GLUT-1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX significantly decreased mRNA expression of HIF-1α and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. The expression of HIF-1α protein was significantly increased at 4 and 8 weeks in tubules in the diabetic rat kidney. PTX tended to decrease HIF-1α protein expression at 8 weeks. To examine whether PTX had a direct effect on renal tubules, normal rat kidney cells were stimulated with CoCl(2) (100 µM), which enhanced HIF-1α mRNA and protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) treatment. PTX had no effect on HIF-1α expression.
conclusionsPTX attenuates tubular hypoxia in the diabetic kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.